T-DXd, studied extensively in the DESTINY-Breast series (1–4), has shown promising results in managing both HER2-positive and HER2-low-expressing breast cancers, significantly impacting the treatment landscape. This evidence concerns the gene ERBB2 and breast carcinoma.